Cocrystal Pharma Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses including SARS-CoV-2, and rhinoviruses. The company employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Key programs include CDI-988, an oral direct-acting 3CL protease inhibitor for the treatment and prevention of norovirus infection, which has received FDA Fast Track designation to accelerate development and regulatory review. Additionally, CC-42344, a novel PB2 inhibitor, is advancing as both oral and inhaled therapeutics for pandemic, seasonal, and avian influenza strains. Cocrystal Pharma Inc. addresses significant unmet medical needs in antiviral medicine, particularly for diseases lacking approved treatments. Founded in 2008 and headquartered in Bothell, Washington, the company operates in the biopharmaceutical sector, contributing to the global effort against viral infections.